| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| 500g |
|
||
| Other Sizes |
| ln Vitro |
4-Chlorocinnamaldehyde (compound 2) (0.01-1000 μM; 72 h) showed no significant cytotoxicity to neonatal rat cardiomyocytes, with a CC50 of 6972.47 μM after 72 h of incubation [1]. 4-Chlorocinnamaldehyde (0.01-1000 μM; 72 h) had a weak inhibitory effect on the replication of Coxsackievirus B3 (CVB3) in neonatal rat cardiomyocytes, with an IC50 of 2109.08 μM and a therapeutic index of 3.31 after 72 h of incubation [1]. 4-Chlorocinnamaldehyde (10 μM; 72 h) inhibited the secretion of CVB3-induced pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in neonatal rat cardiomyocytes [1]. 4-Chlorocinnamaldehyde (10 μM; 12–24 h) inhibited the mRNA and protein expression of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in CVB3-induced neonatal rat cardiomyocytes [1].
|
|---|---|
| ln Vivo |
4-Chlorocinnamaldehyde (compound 2) (20-60 mg/kg; orally; daily; 6 days) did not significantly reduce myocardial pathology scores or viral titers in male BALB/c mice with Coxsackievirus B3-induced viral myocarditis [1].
|
| Cell Assay |
ELISA detection [1]
Cell Types: CVB3-infected neonatal rat cardiomyocytes Tested Concentrations: 10 μM Incubation Duration: 72 hours Experimental Results: Compared with CVB3-infected control cells, the secretion of TNF-α, IL-1β and IL-6 was significantly reduced. Real-time quantitative PCR[1] Cell Types: CVB3-infected neonatal rat cardiomyocytes Tested Concentrations: 10 μM Incubation Duration: 12 h Experimental Results: Compared with CVB3-infected control cells, the expression of TNF-α, IL-1β and IL-6 mRNA was significantly inhibited. Western Blot analysis [1] Cell Types: CVB3-infected neonatal rat cardiomyocytes Tested Concentrations: 10 μM Incubation Duration: 24 hours Experimental Results: Compared with CVB3-infected control cells, the expression of TNF-α, IL-1β and IL-6 proteins was significantly reduced. |
| Animal Protocol |
Animal/Disease Models:BALB/c (a 4-week-old male Coxsackievirus B3-induced viral myocarditis model) [1]
Doses: 20 mg/kg; 40 mg/kg; 60 mg/kg Route of Administration: Oral; Daily; 6 days Experimental Results: There were no statistically significant differences in pathological scores or viral titers between the dosage groups and the model control group. |
| References |
| Molecular Formula |
C9H7CLO
|
|---|---|
| Molecular Weight |
166.60
|
| CAS # |
49678-02-6
|
| Appearance |
White to yellow solid
|
| SMILES |
C(=C/C=O)\C1=CC=C(Cl)C=C1
|
| Synonyms |
trans-p-Chlorocinnamaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿环境中。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~600.24 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.33 mg/mL (19.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (33.3 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0024 mL | 30.0120 mL | 60.0240 mL | |
| 5 mM | 1.2005 mL | 6.0024 mL | 12.0048 mL | |
| 10 mM | 0.6002 mL | 3.0012 mL | 6.0024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
